['psoriatic arthritis']
['tofacitinib 5 mg bid', 'tofacitinib 10 mg bid', 'adalimumab', 'placebo', 'placebo']

        Inclusion Criteria:

          -  Males or females, aged >= 18 years at time of consent.

          -  Have a diagnosis of Psoriatic arthritis (PsA) of >= 6 months

          -  Meet the Classification Criteria of PsA (CASPAR) at time of screening

          -  Must not have been adequately treated with a a traditional non-biologic disease
             modifying anti-rheumatic drug (DMARD).

          -  Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed and
             required

          -  Must not have taken a biologic Tumour Necrosis Factor Inhibitor

          -  Must have 3 or more swollen joints AND 3 or more tender joints

          -  Must have active psoriasis skin lesions

        Exclusion Criteria:

          -  Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with the
             exception of nail psoriasis which is allowed

          -  Pregnant or breast feeding, females of child-bearing potential not using highly
             effective contraception

          -  New York Heart Association Class III and IV congestive heart failure

          -  History of hypersensitivity or infusion reaction to biologic agents

          -  Infection with HIV, hepatitis B virus, hepatitis C virus, or other chronic infection
      